| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/31/2011 | US7951805 Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase |
| 05/31/2011 | US7951804 Inhibitors of coagulation factors; Thrombosis, tumors, myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis; example, 1-(4-chlorophenyl)-3-[2-(1'-methyl-4,4'-bipiperidinyl-1-yl)-2-oxo-1-phenylethyl]urea |
| 05/31/2011 | US7951803 8-heteroarylpurine MNK2 inhibitors for treating metabolic disorders |
| 05/31/2011 | US7951802 Use of 7-azaindoles in the inhibition of c-Jun N-terminal kinase |
| 05/31/2011 | US7951801 Beta-carbolines useful for treating inflammatory disease |
| 05/31/2011 | US7951800 Anti-infective agents |
| 05/31/2011 | US7951799 Lactam compound, a method for producing the same, and a diabetic therapy by administering the same |
| 05/31/2011 | US7951798 Polymorphs of olanzapine hydrochloride |
| 05/31/2011 | US7951797 Substituted diazepan orexin receptor antagonists |
| 05/31/2011 | US7951796 9-amino-acridine derivatives and their use for eliminating misfolded proteins |
| 05/31/2011 | US7951795 Constrained spirocyclic compounds as CGRP receptor antagonists |
| 05/31/2011 | US7951794 Thiophene derivatives |
| 05/31/2011 | US7951793 Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method |
| 05/31/2011 | US7951792 Antimicrobial composition useful for preserving wood |
| 05/31/2011 | US7951791 Amino-substituted tricyclic derivatives and methods of use |
| 05/31/2011 | US7951789 Compounds and pharmaceutical compositions for the treatment of viral infections |
| 05/31/2011 | US7951788 Method of treating cancer and other conditions or disease states using L-cytosine nucleoside analogs |
| 05/31/2011 | US7951787 Phosphoramidate compounds and methods of use |
| 05/31/2011 | US7951785 NFIA in glial fate determination, glioma therapy and astrocytoma treatment |
| 05/31/2011 | US7951784 modified small interfering RNAs (siRNAs) that are stable in vivo and retain the ability to form an A-form helix when in association with a target RNA; gene expression inhibition; for treating amyotrophic lateral sclerosis associated with the activity of a protein specified by a target mRNA |
| 05/31/2011 | US7951780 Antitumor agent |
| 05/31/2011 | US7951772 Tumor-activated prodrug compounds and treatment |
| 05/31/2011 | US7951614 Methods and compositions for the production of monoclonal antibodies |
| 05/31/2011 | US7951592 Compositions and methods for inducing cell dedifferentiation |
| 05/31/2011 | US7951546 Compositions and methods for the diagnosis and treatment of tumor |
| 05/31/2011 | US7951405 Combined treatment with cisplatin and an epidermal growth factor receptor kinase inhibitor |
| 05/31/2011 | US7951403 Method of making pharmaceutical multiparticulates |
| 05/31/2011 | US7951402 Drug delivery particle |
| 05/31/2011 | US7951400 Coated tablet formulation and method |
| 05/31/2011 | US7951398 Pharmaceutical preparation comprising an active dispersed on a matrix |
| 05/31/2011 | US7951397 Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient |
| 05/31/2011 | US7951396 Preparation of nanoliposome-encapsulating proteins and protein-encapsulated nanoliposome |
| 05/31/2011 | US7951395 Rapid release, water permeable self adhesive polymer matrix system; photodynamic therapy and/or diagnosis of skin lesions |
| 05/31/2011 | US7951394 Device and methods of sequential, regional delivery of multiple cyctotoxic agents and directed assembly of wound repair tissues |
| 05/31/2011 | US7951375 Methods of inducing an immune response |
| 05/31/2011 | US7951371 Soluble lymphotoxin-β receptor fusion protein and methods for inhibiting lymphotoxin β-receptor signaling |
| 05/31/2011 | US7951364 CaR receptor as a mediator of migratory cell chemotaxis and/or chemokinesis |
| 05/31/2011 | US7951137 Method and system for terminating an atrial arrhythmia |
| 05/31/2011 | CA2666674C Feed additive and feed |
| 05/31/2011 | CA2649775C Pyridine[3,4-b]pyrazinones |
| 05/31/2011 | CA2634299C Process for preparing inhibitors of nucleoside metabolism |
| 05/31/2011 | CA2623477C Compositions and method for treating pediatric hypogonadism |
| 05/31/2011 | CA2603866C Androgen modulators |
| 05/31/2011 | CA2601716C Methods and compositions for the treatment of attention deficit hyperactivity disorder and hyperphenylalanemia |
| 05/31/2011 | CA2600762C Stable organic peroxide compositions |
| 05/31/2011 | CA2598821C Organoselenium containing compounds and their use |
| 05/31/2011 | CA2586473C Uniform drug delivery therapy |
| 05/31/2011 | CA2583217C 1,3,4-thiadiazole compounds as protein kinase inhibitors |
| 05/31/2011 | CA2555745C Tetrahydroisoquinoline-and tetrahydrobenzazepine derivatives as igf-1r inhibitors |
| 05/31/2011 | CA2542449C Combined preparation for treating sepsis |
| 05/31/2011 | CA2533515C Heteroaryl-tetrahydropyridyl compounds useful for treating or preventing pain |
| 05/31/2011 | CA2521182C Composition for improving cognition and memory |
| 05/31/2011 | CA2517493C Therapeutic patch with polysiloxane matrix comprising capsaicin |
| 05/31/2011 | CA2507657C 2-aminocarbonyl-quinoline compounds as platelet adenosine diphosphate receptor antagonists |
| 05/31/2011 | CA2501734C Novel bicyclic inhibitors of hormone sensitive lipase |
| 05/31/2011 | CA2501365C Inhibitors of akt activity |
| 05/31/2011 | CA2497450C Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| 05/31/2011 | CA2492739C Process for preparing a sterile high molecular weight hyaluronic acid formulation |
| 05/31/2011 | CA2491312C Bioerodible film for ophthalmic drug delivery |
| 05/31/2011 | CA2483241C Novel diazabicyclononene derivatives |
| 05/31/2011 | CA2480470C Inhibitors of nucleoside phosphorylases and nucleosidases |
| 05/31/2011 | CA2475764C New inhibitors of histone deacetylase |
| 05/31/2011 | CA2468747C Use of pramipexole to treat amyotrophic lateral sclerosis |
| 05/31/2011 | CA2466135C Use of propionyl l-carnitine or one of its pharmacologically acceptable salts for the preparation of a medicine for the treatment of la peyronie's disease |
| 05/31/2011 | CA2465750C 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino[4,5-b]-indole-1-carboxamide derivatives, their preparation and therapeutic use |
| 05/31/2011 | CA2455635C Use of thiazole derivatives for preparing a medicine for protecting mitochondria |
| 05/31/2011 | CA2451626C One dose vaccination with mycoplasma hyopneumoniae |
| 05/31/2011 | CA2443488C Mercaptoacetylamide derivatives, a process for their preparation and their use |
| 05/31/2011 | CA2441357C Agent for the prevention and treatment of sexually transmitted diseases-i |
| 05/31/2011 | CA2440012C Highly flexible transdermal therapeutic system having nicotine as active substance |
| 05/31/2011 | CA2430692C Geldanamycin derivative and use of same to treat cancer |
| 05/31/2011 | CA2416566C Depot formulation comprising ceftiofur and peroxidized natural oil |
| 05/31/2011 | CA2412501C Phytoestrogenic isoflavone compositions, their preparation and use thereof for protection against and treatment of radiation injury |
| 05/31/2011 | CA2398539C Myeloid colony stimulating factor and uses thereof |
| 05/31/2011 | CA2385301C Peeling composition |
| 05/31/2011 | CA2369725C Pyrido-thieno-diazepines, method for the production thereof and pharmaceutical compositions containing said pyrido-thieno-diazepines |
| 05/31/2011 | CA2353822C Camptothecin analogs and methods of preparation thereof |
| 05/31/2011 | CA2350054C Improved fast disintegrating tablet |
| 05/31/2011 | CA2319080C Multivalent antibacterial agents |
| 05/31/2011 | CA2231772C Advanced glycation end-product intermediaries and post-amadori inhibition |
| 05/27/2011 | CA2738617A1 Aerosol formulation for the inhalation of beta agonists |
| 05/27/2011 | CA2723119A1 Pharmaceutical compound comprising a strontium salt, vitamin d and a cyclodextrin |
| 05/27/2011 | CA2686587A1 Combination therapy for treating proliferative diseases |
| 05/27/2011 | CA2686584A1 Plasmodium proteases inhibitors and in silico screening methods for identifying the same |
| 05/26/2011 | WO2011063421A1 Cyclodextrin-based polymers for therapeutic delivery |
| 05/26/2011 | WO2011063415A2 Methods for treating mild cognitive impairment |
| 05/26/2011 | WO2011063400A1 Nitroxyl donors for the treatment of pulmonary hypertension |
| 05/26/2011 | WO2011063398A1 Polymorphs and salts of a kinase inhibitor |
| 05/26/2011 | WO2011063382A1 Materials and methods useful for affecting tumor cell growth, migration and invasion |
| 05/26/2011 | WO2011063339A1 Nitroxyl donors for the treatment of pulmonary hypertension |
| 05/26/2011 | WO2011063293A1 Boron-containing small molecules as antihelminth agents |
| 05/26/2011 | WO2011063276A1 7-[3,5-dihydroxy-2- (3-hydroxy-5-phenyl-pent-1-enyl)- cyclopentyl]-n-ethyl-hept-5-enamide (bimatoprost) in crystalline form ii, methods for preparation, and methods for use thereof |
| 05/26/2011 | WO2011063272A1 Amino heteroaryl compounds as beta-secretase modulators and methods of use |
| 05/26/2011 | WO2011063241A1 2,4-pyrimidinediamine compounds and prodrugs thereof and their uses |
| 05/26/2011 | WO2011063233A1 Amino heteroaryl compounds as beta-secretase modulators and methods of use |
| 05/26/2011 | WO2011063181A1 Methods and assays for the treatment of irritable bowel syndrome |
| 05/26/2011 | WO2011063178A2 Intravenous infusion of curcumin and a calcium channel blocker |
| 05/26/2011 | WO2011063164A2 Sustained release cannabinoid medicaments |
| 05/26/2011 | WO2011063159A1 Compounds and methods for kinase modulation, and indications therefor |
| 05/26/2011 | WO2011063150A2 Oral formulation for dexlansoprazole |